ImmuCell (ICCC) Akcie Kurz
ImmuCell Kurz
Tržby rostly o 9,7 % ročně za posledních 19 let na 27,64 Mil. USD. Zisk na akcii klesal o 7,3 % ročně za posledních 10 let. čistá marže společnosti ImmuCell je nyní -3,8 %, dolů z -0,4 % před několika lety.
Cena akcie ImmuCell
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model ImmuCell a analýza akcií
Nejčastější otázky týkající se akcie ImmuCell
ImmuCell Corp operates as a biotechnology company, focusing on the development and commercialization of products that improve the health and productivity of dairy and beef cattle. The company's business model revolves around providing innovative animal health solutions, such as First Defense® for newborn calves, which helps strengthen their immune system and prevent diseases. ImmuCell Corp also offers Mast Out®, an FDA-approved treatment for mastitis in lactating dairy cows. Through its dedication to science-driven research and development, ImmuCell Corp aims to enhance animal well-being, increase farmers' efficiency, and ultimately contribute to a sustainable agriculture industry.
ImmuCell Corp is primarily active in the animal health industry.
The main competitors of ImmuCell Corp in the market include companies such as Zoetis Inc., Elanco Animal Health Inc., and Merck & Co. Inc.
ImmuCell Corp is a renowned biotechnology company specializing in the development and production of innovative, preventative animal health products, focusing primarily on the dairy and beef industries. Founded in 1982 and headquartered in Portland, Maine, ImmuCell has established itself as a leader in the field of animal health through its dedication to improving the well-being and productivity of livestock. The company's flagship product, First Defense®, helps protect newborn calves against common diseases while enhancing their natural immune system. ImmuCell Corp remains committed to research and development, continuously striving to provide cutting-edge solutions for animal health challenges.
ImmuCell Corp has achieved significant milestones in its history. One of the notable accomplishments is the development and commercialization of their flagship product, First Defense®. This groundbreaking product has revolutionized the field of animal health by providing a proactive approach to preventing calf scours. Additionally, ImmuCell Corp has successfully expanded its product portfolio to include prominent offerings such as Wipe Out® Dairy Wipes and California Mastitis Test. The company's commitment to research and innovation has garnered recognition, including the prestigious "Best Places to Work in Maine" award. ImmuCell Corp continues to make strides in the animal health industry, solidifying its position as a leader in innovative solutions that enhance herd productivity and profitability.
ImmuCell Corp is primarily present in the United States.
ImmuCell Corp represents a set of core values and a corporate philosophy aimed at advancing animal health and well-being. The company is committed to developing, manufacturing, and selling products that enhance the health and productivity of animals, with a specific focus on the dairy and beef industries. ImmuCell prioritizes quality, innovation, and sustainability, striving to provide effective solutions for preventing and treating various diseases. By leveraging their expertise in animal health, ImmuCell Corp aims to contribute to healthier livestock populations and more efficient farming practices.
7 analytiků aktuálně hodnotí akcii ImmuCell: 6 doporučuje koupit, 1 držet a 0 prodat. Pro rok 2026 analytici očekávají u ImmuCell tržby 15,14 Mil. USD a zisk na akcii -0,24 USD.
Při aktuálním kurzu se akcie ImmuCell obchoduje za 9,16 EUR (10,25 USD).
Akcie ImmuCell (ICCC) je kótována na 2 burzách, mimo jiné: NASDAQ (ICCC), Frankfurt (IUL.F).
ImmuCell Corp is a US company specializing in the development and marketing of products for the prevention and treatment of animal diseases, particularly in the dairy industry. The company operates in two main divisions: animal health and veterinary diagnostics. In the animal health division, the flagship product is Calf-Guard®, an immunoglobulin preparation used for preventing diarrhea in calves. In the veterinary diagnostics division, the Bovine IgG Rapid Test Kit is a key product that allows farmers to monitor the health of their animals and detect diseases in a timely manner. ImmuCell Corp aims to expand its product pipeline and enter new markets.
Tržby očekávané za ImmuCell činí 15,14 Mil. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za ImmuCell činí -2,17 Mil. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) ImmuCell je aktuálně -42,69. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie ImmuCell.
Poměr ceny k tržbám (P/S) ImmuCell je aktuálně 6,12. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie ImmuCell.
Score kvality pro ImmuCell je 3/10.
ISIN ImmuCell je US4525253062. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN ImmuCell je 885825. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker ImmuCell je ICCC. Symbol tickeru se používá k obchodování akcií ImmuCell na burze.
ImmuCell akcie
ImmuCell Peer Group
ImmuCell Ticker
ImmuCell FIGI
Všechny fundamentální údaje o ImmuCell v podrobné analýze
Naše analýzy akcií společnosti ImmuCell zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti ImmuCell. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: